For close to a decade, U.S. lawyers have pressed price-fixing claims against Chinese companies that produce most of the world’s vitamin C, finally winning a $157 million verdict last year. With that verdict now on appeal, the Chinese government is reasserting its position that the litigation should never have gotten off the ground because the defendants were acting at its behest.
In an amicus brief filed on Monday, the Ministry of Commerce of the People’s Republic of China (MOFCOM) urged the U.S. Court of Appeals for the Second Circuit to reverse the verdict, arguing that defendants North China Pharmaceutical Group Corp. and Hebei Welcome Pharamceutical Co. were unfairly penalized for complying with Chinese law. MOFCOM, which equates itself to a cabinet-level department of the U.S. government, is represented by a Sidley Austin team including Carter Philips, Kwaku Akowuah and Joel Mitnick.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
